FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA supplemental application for XOFIGO (radium-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc. to support changes to the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

SUPPL AP for XOFIGO (RADIUM RA 223 DICHLORIDE)